Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPOLI-1: MM-398 ± 5-fluorouracil/leucovorin vs 5-fluorouracil/leucovorin in metastatic pancreatic cancer
2011-004687-30Phase 3Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Overall survival. Started Dec 2011; status: completed.
02
Drugs
irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-004687-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004687-30.